Keratoconus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Keratoconus Market Outlook
Thelansis’s “Keratoconus Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Keratoconus treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Keratoconus Overview
Keratoconus
is a bilateral and asymmetric cornea disease characterized by progressive
thinning, steepening, irregular astigmatism, and decreased visual acuity.
Environmental and familial factors are associated with an increased risk of
developing the condition. Eye rubbing is also a strong risk factor in the
pathogenesis of keratoconus. Classification systems based on morphological
changes and disease evolution are Morphological (Buxton), Keratometric, Hom’s,
and Amsler-Krumeich. The condition typically develops in the second and third
decades of life and progresses until the fourth decade, when it stabilizes. It
can also develop earlier or later in life. The condition typically affects both
eyes, although with different degrees of severity. While there is no clear
consensus on the signs and symptoms associated with early keratoconus,
subclinical or form-fruste keratoconus is commonly used to describe the early
stages of the disease.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment